[go: up one dir, main page]

AR054347A1 - Combinaciones terapeuticas para el tratamiento o la prevencion de la depresion - Google Patents

Combinaciones terapeuticas para el tratamiento o la prevencion de la depresion

Info

Publication number
AR054347A1
AR054347A1 ARP060101594A ARP060101594A AR054347A1 AR 054347 A1 AR054347 A1 AR 054347A1 AR P060101594 A ARP060101594 A AR P060101594A AR P060101594 A ARP060101594 A AR P060101594A AR 054347 A1 AR054347 A1 AR 054347A1
Authority
AR
Argentina
Prior art keywords
depression
treatment
prevention
therapeutic combinations
combinations
Prior art date
Application number
ARP060101594A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36809594&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR054347(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR054347A1 publication Critical patent/AR054347A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)

Abstract

Se proporcionan combinaciones terapéuticas utiles en el tratamiento o prevencion de la depresion u otros trastornos del temperamento, composiciones farmacéuticas que contienen dichas combinaciones, y su uso en el tratamiento o profilaxis de la depresion u otros trastornos del temperamento. Tales compuestos son de formula (1), o una sal farmacéuticamente aceptable de los mismos, donde cada uno de R1, R2, R3, n, y, y Ar son como de definio y describio en la presente.
ARP060101594A 2005-04-22 2006-04-21 Combinaciones terapeuticas para el tratamiento o la prevencion de la depresion AR054347A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US67404805P 2005-04-22 2005-04-22

Publications (1)

Publication Number Publication Date
AR054347A1 true AR054347A1 (es) 2007-06-20

Family

ID=36809594

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060101594A AR054347A1 (es) 2005-04-22 2006-04-21 Combinaciones terapeuticas para el tratamiento o la prevencion de la depresion

Country Status (13)

Country Link
US (2) US7396857B2 (es)
EP (1) EP1871355A1 (es)
JP (1) JP2008536946A (es)
CN (1) CN101198322A (es)
AR (1) AR054347A1 (es)
AU (1) AU2006239918A1 (es)
BR (1) BRPI0610044A2 (es)
CA (1) CA2604915A1 (es)
GT (1) GT200600163A (es)
MX (1) MX2007012882A (es)
PE (1) PE20061327A1 (es)
TW (1) TW200722081A (es)
WO (1) WO2006116149A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050261347A1 (en) * 2003-10-24 2005-11-24 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
US7435837B2 (en) * 2003-10-24 2008-10-14 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
GT200500297A (es) * 2004-10-21 2006-10-27 Sintesis asimetrica de dehidrobenzofuranos sustituidos
GT200500296A (es) * 2004-10-21 2006-10-02 Sintesis asimetrica de derivados del dehidrobenzofurano
AU2006239930A1 (en) * 2005-04-22 2006-11-02 Wyeth Benzodioxane and benzodioxolane derivatives and uses thereof
CN101203218A (zh) * 2005-04-22 2008-06-18 惠氏公司 苯并呋喃基链烷胺衍生物和其作为5－ht2c激动剂的用途
CN101189004A (zh) * 2005-04-22 2008-05-28 惠氏公司 疼痛的治疗
JP2008538571A (ja) * 2005-04-22 2008-10-30 ワイス ジヒドロベンゾフラン誘導体およびその使用
TW200716595A (en) * 2005-04-22 2007-05-01 Wyeth Corp Chromane and chromene derivatives and uses thereof
CN101203216A (zh) * 2005-04-22 2008-06-18 惠氏公司 二氢苯并呋喃衍生物及其用途
CN101198323A (zh) * 2005-04-22 2008-06-11 惠氏公司 用于治疗或预防精神障碍的治疗组合
AU2006239920A1 (en) * 2005-04-22 2006-11-02 Wyeth Dihydrobenzofuran derivatives and uses thereof
JP2008538784A (ja) * 2005-04-24 2008-11-06 ワイス 膀胱機能を調節するための方法
WO2007112065A2 (en) * 2006-03-24 2007-10-04 Wyeth Methods for treating cognitive and other disorders
AU2008248382B2 (en) * 2007-05-07 2013-07-18 Chelsea Therapeutics, Inc. Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders, or attention deficit disorders
US8198268B2 (en) 2008-10-31 2012-06-12 Janssen Biotech, Inc. Tianeptine sulfate salt forms and methods of making and using the same
WO2011011594A2 (en) * 2009-07-23 2011-01-27 Shriners Hospitals For Children Intracellular toll-like receptors pathways and axonal degeneration
US20120253036A1 (en) 2009-12-11 2012-10-04 Yukinori Nagakura Agent for treating fibromyalgia
CN102250048B (zh) * 2011-06-03 2013-06-05 浙江工业大学 2-苯硒基甲基-2,3-二氢苯并呋喃及其制备与应用
EA034419B1 (ru) * 2014-09-26 2020-02-06 Хьюман Метаболоми Текнолоджис Инк. Способ выбора лекарственного препарата для лечения депрессии
WO2020087031A1 (en) 2018-10-26 2020-04-30 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
US12465611B2 (en) 2019-02-17 2025-11-11 Neurawell Therapeutics Compositions and methods for treatment of depression and other disorders
KR20230066313A (ko) 2020-06-08 2023-05-15 탁토젠 인크 정신 장애 또는 정신적 증강에 유리한 벤조푸란 조성물
TW202220965A (zh) 2020-08-06 2022-06-01 美商塔朵根公司 用於心理疾患或心理增強之２－胺基茚滿化合物

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3513239A (en) 1967-03-15 1970-05-19 Smithkline Corp Pharmaceutical compositions containing 2-aminoalkyl coumaran derivatives and methods of treating depression therewith
US3826835A (en) 1971-01-08 1974-07-30 Ciba Geigy Corp 8-benzofurylmethyl-1,3,8-triazaspiro(4,5)decanes as neuroleptics
JPS59186969A (ja) 1983-04-08 1984-10-23 Yoshitomi Pharmaceut Ind Ltd ベンゾフラン−およびベンゾピランカルボキサミド誘導体
JPH06316563A (ja) 1993-05-06 1994-11-15 Yoshitomi Pharmaceut Ind Ltd アミド化合物
SG47711A1 (en) 1993-06-28 1998-04-17 American Home Prod New treatments using phenehylamine derivatives
US6150402A (en) 1994-08-15 2000-11-21 Loma Linda University Medical Center Natriuretic compounds
AU1106195A (en) 1994-11-09 1996-06-06 Novo Nordisk A/S Heterocyclic compounds, their preparation and use
US5756532A (en) 1995-11-06 1998-05-26 American Home Products Corporation Aminomethyl-2 3 8 9-tetrahydro-7H-1 4-dioxino 2 3-E!-indol-8-ones and derivatives
US6274171B1 (en) 1996-03-25 2001-08-14 American Home Products Corporation Extended release formulation of venlafaxine hydrochloride
DE19909760B4 (de) 1998-04-17 2015-05-21 Merck Patent Gmbh Benzofuran-Derivate
US7045545B1 (en) 1999-01-27 2006-05-16 Eli Lilly And Company Aminoalkylbenzofurans as serotonin (5-HT(2c)) agonists
SE9902267D0 (sv) * 1999-06-16 1999-06-16 Astra Ab New compounds
US20020107244A1 (en) 2001-02-02 2002-08-08 Howard Harry R. Combination treatment for depression
US6969730B2 (en) 2001-03-16 2005-11-29 Abbott Laboratories Amines as histamine-3 receptor ligands and their therapeutic applications
KR100446235B1 (ko) 2001-05-07 2004-08-30 엘지전자 주식회사 다중 후보를 이용한 움직임 벡터 병합 탐색 방법
WO2003029239A1 (en) 2001-10-04 2003-04-10 Wyeth Chroman and benzofuran derivatives as 5-hydroxytryptamine-6 ligands
CA2461381A1 (en) 2001-10-04 2003-04-10 Wyeth Chroman derivatives as 5-hydroxytryptamine-6 ligands
WO2003031439A1 (en) 2001-10-05 2003-04-17 Wyeth Antidepressant chroman and chromene derivatives of 3-(1,2,3,6-tetrahydro-4-pyridinyl)-1h-indole
US20030134835A1 (en) 2002-01-11 2003-07-17 Arthur Hancock Histamine-3 receptor ligands for diabetes conditions
US7208502B2 (en) 2002-01-18 2007-04-24 Maniv Energy Capital Methods of treating conditions associated with an Edg-3 receptor
US20030092770A1 (en) 2002-10-23 2003-05-15 Phil Skolnick Combination therapy for treatment of depression
JPWO2004089410A1 (ja) 2003-04-03 2006-07-06 協和醗酵工業株式会社 神経因性疼痛の予防及び／または治療剤
EP1648455A4 (en) 2003-07-23 2009-03-04 Exelixis Inc MODULATORS OF ALK PROTEIN (ANAPLASTIC LYMPHOMA KINASE) AND METHODS OF USE
US7728155B2 (en) 2003-10-24 2010-06-01 Wyeth Llc Dihydrobenzofuranyl alkanamines and methods for using same as cns agents
US20050261347A1 (en) 2003-10-24 2005-11-24 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
US7435837B2 (en) * 2003-10-24 2008-10-14 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
CA2553084A1 (en) 2004-01-28 2005-08-11 Kissei Pharmaceutical Co., Ltd. Novel benzofuran derivative, medicinal composition containing the same, and uses of these
DE102004030099A1 (de) 2004-06-22 2006-01-12 Grünenthal GmbH Gesättigte und ungesättigte 3-Pyridyl-benzocycloalkylmethyl-amine als Serotonin- und/oder Noradrenalin-Reuptake-Hemmer und/oder µ-Opioidrezeptor-Modulatoren
WO2006000902A1 (en) 2004-06-25 2006-01-05 Pfizer Products Inc. Dihydrobenzofuran compounds and uses thereof
GT200500297A (es) 2004-10-21 2006-10-27 Sintesis asimetrica de dehidrobenzofuranos sustituidos
GT200500296A (es) 2004-10-21 2006-10-02 Sintesis asimetrica de derivados del dehidrobenzofurano
TW200716595A (en) 2005-04-22 2007-05-01 Wyeth Corp Chromane and chromene derivatives and uses thereof
CN101189004A (zh) 2005-04-22 2008-05-28 惠氏公司 疼痛的治疗
JP2008538571A (ja) 2005-04-22 2008-10-30 ワイス ジヒドロベンゾフラン誘導体およびその使用
CN101198323A (zh) * 2005-04-22 2008-06-11 惠氏公司 用于治疗或预防精神障碍的治疗组合
WO2006116148A2 (en) 2005-04-22 2006-11-02 Wyeth (7-arlysubstituted 2, 3-dihydr0-1-benz0furan-2-yl) alkylamines in the treatment' of substance abuse
MX2007013179A (es) 2005-04-22 2008-01-16 Wyeth Corp Formas cristalinas de clorhidrato de {[(2r)-7-(diclorofenil)-5- fluoro-2,3-dihidro-1-benzofurano-2-il]metil}amina.
AU2006239920A1 (en) 2005-04-22 2006-11-02 Wyeth Dihydrobenzofuran derivatives and uses thereof
CN101203216A (zh) * 2005-04-22 2008-06-18 惠氏公司 二氢苯并呋喃衍生物及其用途
CN101203218A (zh) 2005-04-22 2008-06-18 惠氏公司 苯并呋喃基链烷胺衍生物和其作为5－ht2c激动剂的用途
JP2008538784A (ja) 2005-04-24 2008-11-06 ワイス 膀胱機能を調節するための方法
WO2007112065A2 (en) 2006-03-24 2007-10-04 Wyeth Methods for treating cognitive and other disorders

Also Published As

Publication number Publication date
US20060258715A1 (en) 2006-11-16
PE20061327A1 (es) 2007-01-02
US20080269321A1 (en) 2008-10-30
CN101198322A (zh) 2008-06-11
US7396857B2 (en) 2008-07-08
MX2007012882A (es) 2007-12-10
CA2604915A1 (en) 2006-11-02
JP2008536946A (ja) 2008-09-11
AU2006239918A1 (en) 2006-11-02
GT200600163A (es) 2007-03-14
BRPI0610044A2 (pt) 2010-05-25
TW200722081A (en) 2007-06-16
EP1871355A1 (en) 2008-01-02
WO2006116149A1 (en) 2006-11-02

Similar Documents

Publication Publication Date Title
AR054347A1 (es) Combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
GT200900283A (es) "terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario".
UY29384A1 (es) Derivados del ácido2-3s,4r)-4-(((3,4-dicloro-5-metil-1h-pirrol-2-il) carbonil)amino)-1,3-tiazol-5-carboxílico y sus sales, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciónes.
GT200600518A (es) Derivados de pirimidina
AR053162A1 (es) Compuesto 5 - oxo - pirrolidin sustituido, composicion farmaceutica que lo comprende y su uso para preparar un medicamento para el tratamiento del glaucoma.
CL2008001560A1 (es) Compuestos derivados de heterociclo de nitrogenado, moduladores de gamma secretasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades neurodegenerativas como el alzheimer, sindrome de down; kit farmaceutico.
ECSP055867A (es) Derivados de pirrolopirimidina
ECSP088763A (es) Nuevas combinaciones terapéuticas para el tratamiento de la depresión
SV2002000504A (es) Derivados biciclicos sustituidos para el tratamiento del crecimiento celular anormal ref.pc10760/20205/bb
UY32462A (es) Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644
UY30759A1 (es) Compuestos quimicos
SV2009003281A (es) Inhibidores espiro cetona de acetil-coa carboxilasa.0
UY29781A1 (es) Compuestos diazaspiro sustituidos, sales farmacéuticamente aceptables, composiciones farmacéuticas que contienen los compuestos o sales, métodos de preparación y usos
ECSP088871A (es) Derivados de triazolopirazina
MX2009001660A (es) Compuestos de 2,5-dihidroxibenceno para el tratamiento de psoriasis.
UY28923A1 (es) Compuestos terapéuticos: piridina como estructura base
UY31141A1 (es) Compuestos de piperidina y sus usos
UY27685A1 (es) Indolil-urea derivados de tienopiridinas útiles como agentes antiangiogénicos, y procedimientos para su uso
ECSP088250A (es) Derivados de pirazol como agentes terapéuticos
GT200600161A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de los trastornos psicoticos
UY28356A1 (es) Derivados de benzimidazol, composiciones que los contienen, preparaciones de los mismos y sus usos
CR10255A (es) "nuevas composiciones terapéuticas para el tratamiento o la prevención de trastornos psicóticos"
AR064543A1 (es) Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales
UY28357A1 (es) Derivados de benzimidazol, composiciones que los contienen, preparación de los mismos y sus usos
AR057148A1 (es) Combinaciones farmacologicas para el tratamiento de enfermedades de las vias respiratorias

Legal Events

Date Code Title Description
FA Abandonment or withdrawal